In: 新闻报道

 美国宾州,霍舍姆 — 2018年5月18日。 安永会计师事务所 (Ernst & Young) 已宣布Joanne Santomauro为大费城地区年度企业家奖®2018决赛选手,Joanne Santomauro是Ancillare, LP公司的创始人兼CEO,该公司是为制药、生物技术、外包研发和医疗研究机构提供端到端全球临床试验辅助供应链管理服务的领导者。

该奖项旨在表彰那些在创新、财务业绩以及对企业和社区的个人承诺等方面表现出色的企业家。Santomauro被一组独立评委选为决赛选手。

“因为我的前瞻性思维和创新而被大家认可为决赛选手真是一种荣幸,”Santomauro说道:“我很幸运,能够成功地为各个赞助组织管理全球临床供应链,并成为开发创新地、挽救生命的疗法贡献一份力量,为患者服务。”

在Santomauro鼓舞人心的领导下,Ancillare公司从2006年的创业组织发展成为行业领导者,定义并改变了生命科学行业对临床和辅助供应链的认知和管理方式。

这个奖项已进入第32个年头,现已扩展到全球145多个城市和60多个国家的商业领袖。区域奖获得者有资格参加年度企业家全国竞赛 – 战略增长论坛®的高潮环节,它是高增长的市场领先公司的全国最具声望的聚会。

区域奖获奖者将于6月14日星期四在Kimmel表演艺术中心举行的特别盛会上宣布。11月10日将在加利福尼亚州棕榈泉举行的年度企业家奖颁奖典礼上宣布多个国家类别的获奖者以及年度企业家全国总奖。

赞助商
年度企业家奖由安永创办和制作,由SAP America,Merrill Corporation和Ewing Marion Kauffman Foundation在美国全国赞助。在大费城,赞助商还包括PNC银行,Pine Hill集团,Murray Devine & 公司,SolomonEdwardsGroup, Ballard Spahr LLP, Morgan, Lewis & Bockius LLP, Pepper Hamilton LLP和Simkiss & Block。

关于Ancillare, LP
Ancillare是唯一一家专注于全球临床和辅助供应链的组织。Ancillare通过定制的端到端Ancillare供应计划,为全球临床试验的赞助商助力,使新疗法的开发人员能够使用简化的流程,广泛的全球购买力,庞大的仓库网络和经过验证的临床,采购,运营,物流和监管专家团队,优化其临床研究供应链 。Ancillare的一站式运营(A-TKO™)模式通过降低临床试验的总体成本和周期时间,并大大提高价值链各个层面的运营效率,可同时应对临床和辅助供应链的复杂性和全球化。

Ancillare已在100多个国家的80000个临床站点支持了1500多项临床试验,其中包括美国,英国和新加坡的主供应站,以及阿根廷,澳大利亚,巴西,加拿大,智利,中国,哥伦比亚,印度,以色列,日本,韩国,墨西哥,巴拿马,秘鲁,菲律宾,俄罗斯,南非,台湾和乌克兰的战略供应站。要了解更多信息,请访问ancillare.com

关于年度企业家奖®
年度企业家奖®由安永会计师事务所创立,是世界上最负盛名的企业家商业奖项计划,由独立评审团组成,包括企业家和商界,金融界和当地社区的知名领袖。该计划通过鼓励有潜力的人进行创业活动的方式发挥作用,并认可那些以自己的愿景、领导力和成就激励他人的人的贡献。作为同类型中第一个也是唯一一个真正的全球奖项计划,年度企业家庆祝那些正在打造并领导成功的、不断发展的和充满活力的企业的人们,在超过145个城市和60多个国家,以地区奖项,国家奖项和全球奖计划来表彰他们的贡献。请访问 ey.com/eoy了解更多信息。

关于安永的增长市场网络
安永的全球增长市场网络致力于满足高增长公司不断变化的需求。30多年来,我们帮助世界上许多最具活力并雄心勃勃的公司成长为市场领导者。无论是与国际中型企业合作还是早期风险投资支持的企业,我们的专业人士都会利用他们丰富的经验,洞察力和全球资源来帮助您的企业取得成功。更多信息请访问我们的网站ey.com/sgm 或在Twitter上关注我们@EY_Growth

关于安永
安永是保险,税务,交易和咨询服务的全球领导者。我们提供的见解和优质服务有助于建立对资本市场和全球经济体的信任和信心。我们培养杰出的领导者,他们团结一致,向所有利益相关者兑现我们的承诺。通过这样做,我们在为员工,客户和社区建立更好的工作环境方面发挥着关键作用。

安永指的是全球组织,也可能指Ernst&Young全球有限公司的一个或多个成员公司,每个成员公司都是一个独立的法人实体。Ernst&Young全球有限公司是一家英国有限责任公司,不向客户提供服务。欲了解更多与我们组织有关的信息,请访问ey.com。

本新闻由Ernst & Young LLP发布,即全球安永组织的成员之一,旨在向美国的客户提供服务。更多信息请访问ey.com

Jonathan Santomauro对公司和社区的奉献精神受到认可,入选《费城商业期刊》的活力进取新星名单并获得表彰。

美国宾州,霍舍姆—2018年4月17日 全球临床和辅助供应链领导者Ancillare, LP,唯一一家专门为大中型制药、生物技术和医疗器械公司以及外包研发和医疗研究机构提供端到端临床和辅助供应链管理服务的组织,很高兴地宣布其总裁兼联合创始人Jonathan Santomauro被《费城商业期刊》评为“2018年40岁以下40大杰出人物”之一。

“40岁以下40大杰出人物”表彰的是费城地区当前及未来的优秀领导者,认可他们的专业卓越,杰出成就和对社区的贡献。Santomauro从400多个提名者中脱颖而出。

Santomauro在确定对临床和辅助供应链行业的单一焦点方面发挥了重要作用,并且最特别的是,他被视作Ancillare 一站式运营(A-TKO™)端到端解决方案背后的驱动主力,这已经彻底改变了行业对临床供应链的处理方式。通过这种和其他商业模式,Ancillare将继续保持在全球临床供应链行业的最前沿,并将继续对临床试验操作,时间线,现场表现和最终患者体验产生直接影响。

Ancillare已从最初的创业组织发展成为一个在全世界各地雇员多达200多人的全球组织。定义并改变了生命科学行业对临床和辅助供应链的感知和管理方式。如今,全球十大顶级制药公司中的八家,全球五大顶级生物技术公司中的三家以及顶尖的两大临床研究机构,都选择让Ancillare管理自己的I-IV阶段临床试验和辅助供应需求。

“能被评选为《费城商业期刊》“40岁以下40大杰出人物”之一是一种荣誉,”Santomauro说: “我很幸运能够为全球各地患者的临床试验操作和创新疗法的发展带去直接影响。”

Santomauro活跃于当地商业社区,他是YPO(前青年主席组织)费城分会的成员,还是康奈尔大学的创业咨询委员会的长期成员,并在那里获得了工商管理硕士学位和文学学士学位。

Santomauro将于5月10日星期四在费城SugarHouse赌场举行的颁奖典礼上领奖。

关于Ancillare, LP

Ancillare是唯一一家专注于全球临床和辅助供应链的组织。Ancillare通过定制的端到端Ancillare供应计划,为全球临床试验的赞助商助力,使新疗法的开发人员能够使用简化的流程,广泛的全球购买力,庞大的仓库网络和经过验证的临床,采购,运营,物流和监管专家团队,优化其临床研究供应链 。Ancillare的一站式运营(A-TKO™)模式通过降低临床试验的总体成本和周期时间,并大大提高价值链各个层面的运营效率,可同时应对临床和辅助供应链的复杂性和全球化。

Ancillare已在100多个国家的80000个临床站点支持了1500多项临床试验,其中包括美国,英国和新加坡的主供应站,以及阿根廷,澳大利亚,巴西,加拿大,智利,中国,哥伦比亚,印度,以色列,日本,韩国,墨西哥,巴拿马,秘鲁,菲律宾,俄罗斯,南非,台湾和乌克兰的战略供应站。要了解更多信息,请访问Ancillare.com

 

Approaching Brexit deadline, new licensure will enable continuous global clinical trial operations for sponsors and CROs

HORSHAM, PA. — January 31, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has been awarded a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

The award, which comes in response to the United Kingdom’s anticipated departure from the E.U.—commonly called “Brexit”—will allow Ancillare to continue to support study sponsors’ European needs, even while Brexit’s impact on pharmaceutical supply chains remains unclear. The licensure is a critical victory for the dozens of study sponsors, CROs and MROs for whom the U.K. market is a vital link in complex, global clinical trial portfolios and supply chains.

“I think [the license is] a testament to the integrity and dedication of our global team,” said Joanne Santomauro, CEO, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities—including procurement, holding, supply and export—from its European regional office and master depot in Milton Keynes.

“I’m proud that Ancillare has emerged even better equipped to meet the clinical and ancillary supply chain needs of study sponsors,” Santomauro added.

In response to its confirmed regulatory compliance status, as well as ongoing Brexit requirements, Ancillare anticipates adding staff at its United Kingdom office, in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific. Ancillare expects to announce the staff changes later in Q1 2018.

 

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit ancillare.com.

HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.

 

HORSHAM, PA. – Ancillare, LP, the leader in end-to-end global clinical trial ancillary supply chain management services for pharmaceutical, biotechnology, contract research and medical research organizations, announced today the appointment of Nitin Jain to a new position as Vice President of the Asia-Pacific (APAC) region.
Nitin will focus on driving operational excellence to support our client’s clinical supply chain needs and oversee the complete end-to-end supply chain management operations of Ancillare’s Singapore Master Depot. Nitin brings to Ancillare over 18 years of business development, general management, strategic alliances, supply chain management and operations experience in pharmaceutical, biotechnology and contract research organizations around the world. Nitin has held senior positions at INC Research, Covance, Theorem Clinical Research and Worldwide Clinical Trials.
“We see significant growth potential in the APAC region. Nitin’s extensive experience and strong drive makes him a great fit to lead our operations and growth in the APAC region,” said Joanne Santomauro, Chief Executive Officer at Ancillare. “By expanding our operations in Asia-Pacific this strengthens our ability to provide our clients with a single source for all their clinical trial supply chain needs.”

Singapore along with our strategic depots in China and Korea will provide Ancillare with the gateway to the entire APAC region by incorporating standard processes and procedures under one quality driven operation. The Singapore Operation will augment Ancillare’s strategic and master depot network so that our sponsors’ clinical operations leaders will have one point of expert contact and one clinical supply chain to manage all global trials needs from pre-protocol launch and first patient/first visit through last patient/last visit, site closeout and reclamation.

About Ancillare, LP
Ancillare, LP has extensive experience delivering cost savings and efficiencies to supply chains, with a complete turn-key approach for managing the pharmaceutical, biotechnology, contract research and medical research organizations’ clinical trial supply chains with a singular focus. Our turn-key global model (A-TKOTM) centralizes supply operations which accelerates the processes, lowers costs and mitigates risk by making clinical supply chains more efficient, cost-effective and global.

Our capabilities include pre-protocol analysis and planning, contribution to overall program feasibility assessments and timeline development, product sourcing and procurement, forecasting and budgeting, large and small equipment and consumables management, patient retention and recruitment materials, customs clearance, import/export (including IOR/EOR), storage, kitting, distribution and returns management/disposition (including destruction, refurbishment/recalibration and redeployment) on a global level.

Ancillare has master depots in United States, United Kingdom and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan and Ukraine. To learn more, visit ancillare.com or contact us via LinkedIn, Twitter and Facebook.

HORSHAM, PA.–Ancillare, LP’s Joanne Santomauro, Chief Executive Officer and Founder, is being recognized by Marcum LLP and Philadelphia SmartCEO as a finalist for their 2016 Marcum Innovator of the Year award.

The Marcum Innovator of the Year award honors business leaders who have developed products and services that improve the quality of life and business practice in Philadelphia. Finalists are pioneering new advancements in the biotechnology, healthcare, business services, manufacturing, real estate and technology industries. The winners will be announced on October 26, 2016 at the Sugarhouse Casino in Philadelphia, PA.

“I am honored to be recognized as a Marcum Innovator of the Year finalist. This recognition shows the dedication, support, commitment and excellence of the entire organization.” said Joanne Santomauro.

With Joanne’s forward thinking, she was able to create the ancillary supply chain management industry. Prior to the company’s launch in 2006, pharmaceutical, biotechnology and medical research organizations had little transparency and a lack of understanding of the associated costs, processes, regulatory and compliance requirements of the clinical supply chain. Over the last decade Joanne took the company to explosive growth around the world through dedication, innovative solutions including the Ancillare Turn Key Operative Model (A-TKO) and cutting-edge processes.

About Ancillare, LP
Ancillare, LP has extensive experience delivering cost savings and efficiencies to supply chains, with a complete turn-key approach for managing the pharmaceutical, biotechnology, contract research and medical research organizations’ clinical trial supply chains with a singular focus. Our turn-key global model (A-TKO) centralizes supply operations which accelerates the processes, lowers costs and mitigates risk by making clinical supply chains more efficient, cost-effective and global.
Our capabilities include pre-protocol analysis and planning, contribution to overall program feasibility assessments and timeline development, product sourcing and procurement, forecasting and budgeting, large and small equipment and consumables management, patient retention and recruitment materials, customs clearance, import/export (including IOR/EOR), storage, kitting, distribution and returns management/disposition (including destruction, refurbishment/recalibration and redeployment) on a global level.

Ancillare has managed the supply chain for top pharmaceutical and CRO organizations and has successfully transported goods to 100 countries. Ancillare has master depots in United States, United Kingdom and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan and Ukraine. To learn more, visit www.ancillare.com or contact us via LinkedIn, Twitter and Facebook.